Hycor Shares Fall After Purchase Talks End
- Share via
Hycor Biomedical Inc. shares slumped after the maker of medical diagnostic products said it’s no longer in talks with potential acquirers.
The Garden Grove company’s stock, which had dipped 11 cents to $5.49 a share during regular Nasdaq trading, fell as much as $2.50 to $2.99 after hours.
The company said it’s holding discussions with other firms regarding possible product distribution arrangements, both regional and worldwide.
Hycor’s products include test kits designed to identify autoimmune diseases.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
